NEW YORK (GenomeWeb News) – Med BioGene today said that its commercial partner, Precision Therapeutics, has been certified to perform Med BioGene's lung cancer test out of Precision's Pittsburgh laboratory.
The test, called GeneFx Lung, is a gene expression test for identifying patients with early stage non-small cell lung cancer who, after surgical removal of their tumor, are at higher or lower risks for mortality. Med BioGene and Precision reached a licensing agreement for the test, previously called LungExpress Dx, in 2011.
Med BioGene, based in Vancouver, British Columbia, said that Precision will have discussions with payors "to better understand the current landscape and the specific needs of relevant payors as they apply to GeneFx Lung." The timing of the launch will be determined based on the discussions.